Recommendations for the selection of nucleoside analogues as antihuman
herpesvirus drugs: A real-world analysis of reported cases from the FDA
adverse event reporting system
Abstract
Objective: Based on the discovery and summary of adverse drug reactions
of nucleotide analogues against herpes virus drugs, this study aims to
analyze the situations of ADRs in the real world, put forward reasonable
drug use recommendations, refine the rules of use, and formulate
necessary alternative strategies to provide protection against herpes
virus infection, and provide guidance and reference for the rational and
individualized use of clinical drugs. Methods: All ADRs data of the
drugs from the Q1 of 2004 to the Q4 of 2022 were obtained from the FDA
Adverse Event Reporting System database. Duplicate reports, reports with
uncertain information, and other reports containing abnormal information
were excluded from the obtained data, and the data with more than 3
reports were selected. Apply the ROR, PRR and BCPNN in the
disproportionality analysis for data mining . Results: All data from the
Q1 of 2004 to the Q4 of 2022 were screened from the FAERS database. For
ADEs with high frequency SOC level, we found that several important
signals, including ADEs of ACV, GCV and VACV, simultaneously involved
the following SOC systems: kidney and urinary system diseases, nervous
system disease, skin and subcutaneous tissue diseases and mental
diseases. Conclusion: Analysis of the FAERS database suggests that in
addition to paying attention to efficacy, drug administration should be
individualized according to the specific condition and potential risk of
disease.